Moderate to Severe Plaque Psoriasis - Pipeline Insight, 2024

This “Moderate to Severe Plaque Psoriasis- Pipeline Insight, 2024” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Moderate to Severe Plaque Psoriasis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Moderate to Severe Plaque Psoriasis: Understanding

Moderate to Severe Plaque Psoriasis: Overview

Moderate to Severe Plaque Psoriasis is the most common type of psoriasis. Those thick, scaly patches that develop on the skin are called plaques (placks). About 80% to 90% of people living with psoriasis get plaques, so they have plaque (plack) psoriasis. It is an autoimmune disease in which skin cells rapidly build up, forming scales and dry, itchy patches that flake off. Scientists don't yet fully understand the mechanisms behind autoimmune diseases like Moderate to Severe Plaque Psoriasis, but it is believed that a person's genetics play a central role. Around a third of people with psoriasis have a family history of the disease and evidence of chromosomal mutations on specific locations of a gene (known as PSORS1 through PSORS9).Other causes of Moderate to Severe Plaque Psoriasis, including past infections or toxic exposure, but most are hypothetical at best. Chronic Moderate to Severe Plaque Psoriasis, also known as psoriasis vulgaris, typically appears as raised patches of inflamed skin covered with silvery-white scales (plaques). The plaques are most commonly found on the elbows, knees, scalp, and back. Moderate to Severe Plaque Psoriasis can also affect the nails, causing discoloration, pitting, and even detachment of the nail from the nail bed. Moderate to Severe Plaque Psoriasis can often worsen during an infection, when a person is stressed, or if the skin is injured. Scratching only makes things worse, causing bleeding and a visible thickening of the affected skin. Symptoms can come and go, often staying in remission for months and even years at a time before flaring up for no apparent reason. In some cases, the symptoms may be cyclic and even seasonal. Moderate to Severe Plaque Psoriasis is most often diagnosed by the appearance of the skin. No special blood tests or diagnostic exams are usually needed. But since psoriasis can look like eczema and other skin diseases, diagnosing it can be difficult. In some cases, doctor needs to do a biopsy. Aside from being uncomfortable, moderate to Severe Plaque Psoriasis can be a distressing condition, sometimes undermining a person's confidence and sense of wellbeing. Luckily, the treatment of psoriasis has advanced considerably in recent years in tandem with an ever-widening understanding of immunology and autoimmunity. Current treatment options include: Topical corticosteroids, which can be used continuously but generally no longer than eight weeks (due to the risk of thinning skin), Phototherapy, in which artificial ultraviolet light is used to penetrate the skin and slow the growth of skin cells, Vitamin D3 analogs, which appear to slow the production of skin cells, Retinoids, chemical compounds related to vitamin A that regulate the production of skin cells. Psoriasis can't be cured. The patient probably goes through cycles where the rash looks better and then flares up again. The goal of treatment is fewer and less severe flare-ups.

“Moderate to Severe Plaque Psoriasis- Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Moderate to Severe Plaque Psoriasis pipeline landscape is provided which includes the disease overview and Moderate to Severe Plaque Psoriasis treatment guidelines. The assessment part of the report embraces, in depth Moderate to Severe Plaque Psoriasis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Moderate to Severe Plaque Psoriasis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Moderate to Severe Plaque Psoriasis R&D. The therapies under development are focused on novel approaches to treat/improve Moderate to Severe Plaque Psoriasis.

Moderate to Severe Plaque Psoriasis Emerging Drugs Chapters

This segment of the Moderate to Severe Plaque Psoriasis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Moderate to Severe Plaque Psoriasis Emerging Drugs

BMS-986165 : Bristol-Myers SquibbDeucravacitinib (BMS-986165) is a first-in-class, oral, selective tyrosine kinase 2 (TYK2) inhibitor with a unique mechanism of action. Deucravacitinib is the first and only TYK2 inhibitor in clinical studies across multiple immune-mediated diseases. Bristol Myers Squibb scientists designed deucravacitinib to selectively target TYK2, thereby inhibiting signaling of interleukin (IL)-12, IL-23 and Type 1 interferon (IFN), key cytokines involved in psoriasis pathogenesis. Due to the innovative design of deucravacitinib, Bristol Myers Squibb earned recognition with the 2019 Thomas Alva Edison Patent Award for the science underpinning the clinical development of deucravacitinib. Deucravacitinib is being studied in multiple immune-mediated diseases, including psoriasis, psoriatic arthritis, lupus and inflammatory bowel disease.

AK111: Akeso BiopharmaAK111 is a novel drug targeting IL-17A of autoimmune treatment diseases independently developed by the Company. AK111 is intended to be used for the treatment of psoriasis, ankylosing spondylitis and axial spondylitis. Through combination of competitive blockers, namely IL-17A and IL-17RA, and blocking the biological activities of IL-17, AK111 has reached the efficacy in immune-related diseases in clinical therapies. Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Moderate to Severe Plaque Psoriasis.

Moderate to Severe Plaque Psoriasis: Therapeutic Assessment

This segment of the report provides insights about the different Moderate to Severe Plaque Psoriasis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Moderate to Severe Plaque Psoriasis

There are approx. 30+ key companies which are developing the therapies for Moderate to Severe Plaque Psoriasis. The companies which have their Moderate to Severe Plaque Psoriasis drug candidates in the most advanced stage, i.e. Pre-Registration, Bristol-Myers Squibb.

Phases

This report covers around 30+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Moderate to Severe Plaque Psoriasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Moderate to Severe Plaque Psoriasis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Moderate to Severe Plaque Psoriasis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Moderate to Severe Plaque Psoriasis drugs.

Moderate to Severe Plaque Psoriasis Report Insights

• Moderate to Severe Plaque Psoriasis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Moderate to Severe Plaque Psoriasis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Moderate to Severe Plaque Psoriasis drugs?
• How many Moderate to Severe Plaque Psoriasis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Moderate to Severe Plaque Psoriasis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Moderate to Severe Plaque Psoriasis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Moderate to Severe Plaque Psoriasis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Bristol-Myers Squibb
• Akeso Biopharma
• Jiangsu Hengrui Medicine
• Nimbus Therapeutics
• Sun Pharmaceutical Industries Limited
• Suzhou Zelgen Biopharmaceuticals
• GC Cell Corporation
• Bioeq GmbH
• Dong-A ST Co., Ltd.
• Can-fite Biopharma
• Bio-thera solutions
• AbbVie
• Sinocelltech
• Jansen research and development
• Innovent Biologics
• Aurigene discovery
• Affibody
• GlaxoSmithKline
• Abcentra

Key Products

• BMS-986165
• SHR 1314
• Ebdarokimab
• NDI 034858
• SCD-044
• Jaktinib
• CT 303
• FYB202
• DMB-3115
• CF101
• BAT2206
• ABP 654
• SCT630
• SCD-044
• NDI-034858
• JTE-451
• JNJ-77242113
• IBI112
• Cedirogant
• AUR101
• ABY-035
• GSK2982772

This product will be delivered within 1-3 business days.